185 related articles for article (PubMed ID: 27522991)
61. [A case of successful treatment with intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus].
Mukai Y; Takeda Y; Nakahira S; Kawashima H; Hamanaka M; Uchiyama C; Kanemura T; Takeno A; Okishiro M; Suzuki R; Egawa C; Taniguchi H; Nakata K; Miki H; Kato T; Tamura S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1815-8. PubMed ID: 23267896
[TBL] [Abstract][Full Text] [Related]
62. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
Wong RJ; Ahmed A; Gish RG
Clin Liver Dis; 2015 May; 19(2):309-23. PubMed ID: 25921665
[TBL] [Abstract][Full Text] [Related]
63. Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3.
Okuda H; Saito A; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2005 May; 20(5):759-64. PubMed ID: 15853991
[TBL] [Abstract][Full Text] [Related]
64. [Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up].
Ishida H; Matsuo S; Inoue Y
Rinsho Byori; 2010 Nov; 58(11):1065-72. PubMed ID: 21229703
[TBL] [Abstract][Full Text] [Related]
65. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
[TBL] [Abstract][Full Text] [Related]
66. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
[TBL] [Abstract][Full Text] [Related]
67. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
[TBL] [Abstract][Full Text] [Related]
68. Relationship between pathologic prognostic factors and abnormal levels of des-gamma-carboxy prothrombin and alpha-fetoprotein in hepatocellular carcinoma.
Sakon M; Monden M; Gotoh M; Kanai T; Umeshita K; Nakano Y; Mori T; Sakurai M; Wakasa K
Am J Surg; 1992 Feb; 163(2):251-6. PubMed ID: 1371207
[TBL] [Abstract][Full Text] [Related]
69. Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma.
Yamazaki S; Takayama T; Kurokawa T; Shimamoto N; Mitsuka Y; Yoshida N; Higaki T; Sugitani M
BMC Surg; 2020 Sep; 20(1):201. PubMed ID: 32928172
[TBL] [Abstract][Full Text] [Related]
70. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
[TBL] [Abstract][Full Text] [Related]
71. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin.
Gotoh M; Nakatani T; Masuda T; Mizuguchi Y; Sakamoto M; Tsuchiya R; Kato H; Furuta K
Jpn J Clin Oncol; 2003 Oct; 33(10):522-6. PubMed ID: 14623921
[TBL] [Abstract][Full Text] [Related]
72. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.
Koike Y; Shiratori Y; Sato S; Obi S; Teratani T; Imamura M; Yoshida H; Shiina S; Omata M
Cancer; 2001 Feb; 91(3):561-9. PubMed ID: 11169939
[TBL] [Abstract][Full Text] [Related]
73. The Half-Life of Serum Des-Gamma-Carboxy Prothrombin Is a Prognostic Index of Survival and Recurrence After Liver Resection for Hepatocellular Carcinoma.
Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Uesaka K
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):921-928. PubMed ID: 27638677
[TBL] [Abstract][Full Text] [Related]
74. Elevated Alfa-Fetoprotein and Des-Gamma-Carboxy Prothrombin Levels Predict Poor Outcomes After Liver Transplantation for Hepatocellular Carcinoma Beyond the Japan Criteria.
Ishii M; Ibuki S; Morinaga J; Shimata K; Hirukawa K; Isono K; Honda M; Sugawara Y; Inomata Y; Hibi T
Transplant Proc; 2023 Apr; 55(3):606-612. PubMed ID: 37005157
[TBL] [Abstract][Full Text] [Related]
75. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma.
Kato H; Yoshida H; Taniguch H; Nomura R; Sato K; Suzuki I; Nakata R
World J Gastroenterol; 2015 Dec; 21(46):13101-12. PubMed ID: 26673627
[TBL] [Abstract][Full Text] [Related]
76. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Kudo M
J Gastroenterol Hepatol; 2010 Mar; 25(3):439-52. PubMed ID: 20370723
[TBL] [Abstract][Full Text] [Related]
77. Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria.
Sakaguchi T; Suzuki S; Morita Y; Oishi K; Suzuki A; Fukumoto K; Inaba K; Nakamura S; Konno H
Surg Today; 2010 Jul; 40(7):638-45. PubMed ID: 20582515
[TBL] [Abstract][Full Text] [Related]
78. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
Inoue S; Nakao A; Harada A; Nonami T; Takagi H
Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
[TBL] [Abstract][Full Text] [Related]
79. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
[TBL] [Abstract][Full Text] [Related]
80. Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma.
Kim SU; Park JH; Kim HS; Lee JM; Lee HG; Kim H; Choi SH; Baek S; Kim BK; Park JY; Kim DY; Ahn SH; Lee JD; Han KH
Yonsei Med J; 2015 Sep; 56(5):1296-306. PubMed ID: 26256972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
